Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $1.2 million.

  • Niagen Bioscience's Change in Accured Expenses rose 35.84% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 398.75%. This contributed to the annual value of $1.2 million for FY2024, which is 44.06% down from last year.
  • Latest data reveals that Niagen Bioscience reported Change in Accured Expenses of $1.2 million as of FY2024, which was down 44.06% from $2.2 million recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Change in Accured Expenses ranged from a high of $2.2 million in FY2023 and a low of $348,000 during FY2021.
  • Over the past 3 years, Niagen Bioscience's median Change in Accured Expenses value was $1.2 million (recorded in 2024), while the average stood at $1.4 million.
  • In the last 5 years, Niagen Bioscience's Change in Accured Expenses skyrocketed by 1,566.99% in 2020 and then tumbled by 79.73% in 2021.
  • Over the past 5 years, Niagen Bioscience's Change in Accured Expenses (Yearly) stood at $1.7 million in 2020, then plummeted by 79.73% to $348,000 in 2021, then surged by 145.98% to $856,000 in 2022, then skyrocketed by 151.87% to $2.2 million in 2023, then crashed by 44.06% to $1.2 million in 2024.